Alligator Bioscience AB Last day of trading in paid subscription shares (Sw. BTA)
STOCKHOLM, Feb. 23, 2021 /PRNewswire/ -- Last day of trading in BTA in Alligator Bioscience AB ("Alligator" or the "Company") will be Friday February 26, 2021 and stop day will be Tuesday March 2, 2021.
Through the rights issue, which ended on January 25, 2021, Alligator raised approximately SEK 86m before deduction of issue related costs.
The rights issue has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and last day of trading in Alligator's BTA will be February 26, 2021. Stop day will be March 2, 2021. Shares are estimated to be delivered on the shareholders' account on March 4, 2021.
Redeye AB acts as financial adviser, Setterwalls Advokatbyrå AB acts as legal adviser and Aktieinvest FK AB acts as issuing agent in connection with the rights issue.
For more information, please contact:
Per Norlén, CEO
Phone: +46 46 540 82 00
Marie Svensson, CFO
Phone: +46 46 540 82 03
This information was submitted for publication, through the agency of the contact persons set out above, at 4.00 p.m. CET on February 23, 2021.
About Alligator Bioscience AB
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition,
the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in Alligator. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for shares in Alligator has only been made through the prospectus that was published by the Company on December 30, 2020 (the "Prospectus"). The Prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on http://www.alligatorbioscience.com. The approval of the Prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the shares or any other securities. This release is however not a prospectus in accordance to the definition in the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation") and this announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares or other securities in Alligator. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the rights issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety.